The United States Food and Food Administration expanded its approval against the respiratory syncitial virus (RSV) of modern Thursday to include adults under 60 years old with greater risk of disease.
Previously, the vaccine, known as Mesvia, had been licensed for use for those over 60 years.
Mesvia’s approval occurred after Modern performed a late clinical trial that shows that the vaccine helped increase immune responses in younger adults.
According to a higher risk of RSV, more than a third of adults between the ages of 18 and 59 are at least an underlying condition that puts them at greater risk Modern.
“RSV represents a serious risk to health for adults with certain chronic conditions, and current approval marks an important step forward in our ability to protect additional populations from serious diseases of RSV,” said Stéphane Banll, Modern CEO, in a press release. “We appreciate the review of the FDA and thank all the participants in our clinical essay, as well as the modern team for their dedication to protect people against RSV.”
A sign marks the headquarters of the manufacturer of the coronavirus disease (COVID-19) in Cambridge, Massachusetts, April 28, 2022.
Brian Snyder/Reuters
Although the FDA approves vaccines and can expand approvals for certain age groups, the centers for disease control and prevention establish recommendations on who should obtain vaccines and when.
Currently, the CDC recommends Vaccination by RSV only for those over 75 and for those of 60 years or more with a higher risk.
The Independent Vaccine Advisory Committee of the CDC must vote to recommend that the new age group be eligible for the taking, followed by a final recommendation of the CDC director.
Earlier this week, Kennedy withdrew the 17 members sitting from the committee and replaced them with eight new members. It is not clear how the new panel members will decide to address the recommendations for the RSV vaccine.
Until Friday, the role of director of the CDC is still the vacancy and health secretary and human services, Robert F. Kennedy Jr., has been making final recommendations. At an April meeting, the previous advisory committee voted to recommend Vaccination by RSV for 50 to 59 years with a higher risk of disease, but Kennedy did not adopt the recommendations.
On the other hand, it seems that Kennedy plans that the new committee re -analyzes the recommendations for RSV vaccination, as well as discussing vaccines against HPV and Covid in their meeting scheduled for June 25 and June 27
The modern RSV vaccine is based on RNM technology, which some of the new members have expressed skepticism, especially in relation to COVID-19 vaccines.
Despite the availability, vaccination by RSV has been delayed. As of April 26The last date for which the CDC data is available, it is estimated that 47.5% of adults of 75 years or over and 38.1% of adults from 60 to 74 years, with a high -risk condition informed once they received a vaccine against the RSV.
